Last updated: November 1, 2026
Parlodel is the original branded formulation of bromocriptine mesylate, an ergot-derived dopamine agonist. Its commercial profile is mature and largely genericized. Revenue is concentrated in low-volume specialty indications, while generic bromocriptine and alternative dopamine agonists limit pricing power. Public filings do not identify standalone Parlodel revenue, and the product is not a material separately reported asset for major pharmaceutical companies.
What is Parlodel and how is it used?
Parlodel contains bromocriptine mesylate, a dopamine D2 receptor agonist with additional activity at serotonin and adrenergic receptors. The FDA-approved product has been used in several indications:
| Indication |
Commercial relevance |
| Hyperprolactinemia |
Core historical use; treatment of prolactinomas, galactorrhea, amenorrhea and infertility associated with elevated prolactin |
| Acromegaly |
Niche use; generally displaced by newer somatostatin analogs, pegvisomant and cabergoline |
| Parkinson's disease |
Historical use; largely replaced by newer dopamine agonists and levodopa-based regimens |
| Type 2 diabetes |
Separate bromocriptine formulation, Cycloset, rather than the traditional Parlodel product |
Parlodel is supplied in oral dosage forms, including 2.5 mg tablets and 5 mg capsules in historical U.S. labeling. The product requires dose titration because nausea, vomiting, orthostatic hypotension, dizziness and neuropsychiatric effects can limit use [1].
Bromocriptine is also marketed in generic form. The active ingredient is therefore commercially available without dependence on the Parlodel brand.
When did Parlodel lose market exclusivity?
Parlodel lost practical market exclusivity decades ago. Bromocriptine was approved in the United States in the late 1970s and early 1980s, and generic products have been available for many years. Any original composition-of-matter protection has expired.
| Milestone |
Approximate timing |
Market effect |
| U.S. approval of bromocriptine product |
Late 1970s to early 1980s |
Established the original branded market |
| Generic bromocriptine approvals |
Historical, prior to the modern generic era |
Removed brand exclusivity |
| Parlodel indication expansion |
Historical |
Increased clinical use but did not create durable commercial protection |
| Cycloset approval |
2009 |
Added a separately regulated bromocriptine formulation for type 2 diabetes |
| Current market |
Generic-dominated |
Brand pricing power and promotional investment are limited |
The precise U.S. approval history differs by product, dosage form and indication. FDA records identify Parlodel under NDA 017962 and distinguish it from Cycloset, which has a separate NDA and regulatory profile [2,3].
What patents protect Parlodel?
No active, commercially material U.S. patent estate is generally associated with the original Parlodel bromocriptine product.
Patent categories
| Patent category |
Parlodel position |
| Active ingredient patent |
Expired |
| Original formulation patent |
Expired or commercially immaterial |
| Method-of-use patents |
Historical claims are not a meaningful barrier to generic bromocriptine |
| Manufacturing patents |
May exist at the supplier level but do not generally block finished-dose generic entry |
| Device or delivery-system patents |
Not relevant to conventional Parlodel tablets and capsules |
| Pediatric exclusivity |
No current exclusivity barrier |
| Orphan exclusivity |
No active orphan exclusivity associated with the conventional product |
The Orange Book is the controlling U.S. source for listed patents and regulatory exclusivity. A drug with no current listed patents can still face commercial or regulatory constraints, but those constraints do not recreate brand exclusivity. Orange Book status should be checked by specific NDA, dosage form and current edition because listings can change over time [4].
What is the Orange Book status of Parlodel?
Parlodel has the regulatory profile of an old, off-patent small-molecule drug. The relevant FDA records are the original NDA and associated supplements, while generic bromocriptine products are approved through abbreviated new drug applications.
The commercial implications are direct:
- Generic manufacturers do not need to develop a new clinical efficacy program for ordinary bromocriptine tablets or capsules.
- Abbreviated applications can rely on the reference product’s established safety and efficacy record.
- Paragraph IV litigation is unlikely to be a major current issue because the principal exclusivity period ended long ago.
- Any future patent dispute would more likely concern a new formulation, manufacturing process or separate bromocriptine product than traditional Parlodel.
How many patents cover Parlodel?
The number of active, enforceable U.S. patents materially blocking generic Parlodel entry is effectively zero based on the product’s age and generic availability.
That conclusion differs from the number of historical patents that may appear in patent databases. Patent families can include expired composition, formulation, process or use claims. Those records do not establish current commercial protection.
Patent risk is more relevant for newer bromocriptine products. A sponsor could seek protection for:
- Modified-release dosing.
- Combination products.
- New delivery systems.
- Improved tolerability or dose-escalation regimens.
- New therapeutic indications.
- Specific manufacturing processes or crystal forms.
Such patents would protect the later product only if they satisfy validity and infringement requirements. They would not restore exclusivity to conventional Parlodel.
What is the financial trajectory of Parlodel?
Parlodel’s financial trajectory follows the standard pattern for an old branded medicine:
- Initial growth from new indications and specialist adoption.
- Erosion after generic entry.
- Reduced brand promotion and distribution.
- Continued low-level demand from physicians who value clinical familiarity or patients who remain stable on the product.
- Generic substitution and therapeutic substitution that limit price expansion.
Novartis and other large pharmaceutical companies do not generally report Parlodel as a standalone revenue line. Public company filings typically aggregate mature products within broader portfolios, and Parlodel does not appear to be a separately material reporting segment [5].
Revenue exposure
| Revenue driver |
Effect on Parlodel |
| Generic substitution |
Strongly negative |
| Endocrinology demand |
Supports residual volume |
| Parkinson's disease use |
Limited by newer therapies |
| Acromegaly use |
Limited by higher-value specialty alternatives |
| Brand loyalty |
Provides some persistence but little pricing leverage |
| Reimbursement |
Favors lower-cost generic products |
| Supply continuity |
Can support brand demand during generic shortages |
| International sales |
Potentially meaningful in markets where the brand remains recognized |
The most important commercial variable is not population growth. It is whether a patient or prescriber has a reason to use bromocriptine rather than cabergoline, newer Parkinson's treatments, or modern acromegaly therapies.
How does Parlodel compare with cabergoline?
Cabergoline is the principal pharmacologic comparator in hyperprolactinemia. It is generally dosed less frequently and is often preferred because of convenience and tolerability. Bromocriptine remains clinically relevant when cabergoline is unsuitable, unavailable, contraindicated, or not selected by the treating physician.
| Factor |
Parlodel / bromocriptine |
Cabergoline |
| Drug class |
Dopamine agonist |
Dopamine agonist |
| Typical dosing burden |
More frequent titration and dosing |
Less frequent dosing |
| Hyperprolactinemia position |
Established, often generic |
Often preferred in practice |
| Pregnancy experience |
Long historical exposure |
Increasingly used, but product-specific clinical decisions apply |
| Pricing |
Low generic pricing |
Generic pricing, often commercially competitive |
| Brand value |
Limited |
Brand Dostinex value also largely eroded |
| Market growth |
Mature or declining |
Larger relative role in prolactin management |
This substitution dynamic constrains any recovery in Parlodel revenue even if the underlying hyperprolactinemia market expands.
What generic entry risks exist for Parlodel?
Generic entry is already established, so the relevant risk is continuing erosion rather than a future first generic launch.
Generic competition
Bromocriptine products have been marketed by multiple generic manufacturers over time, including large multinational and specialty-generic companies. Manufacturer participation can vary by strength, dosage form, geography and supply conditions.
Generic competition affects Parlodel through:
- Lower average selling prices.
- Pharmacy substitution.
- Reduced physician incentive to prescribe the brand.
- Lower promotional spending.
- Greater payer pressure.
- Greater vulnerability to formulary exclusion.
The main residual risk to the brand is a gradual decline in prescriptions and distribution rather than a sudden patent-driven loss.
Are there Paragraph IV challenges to Parlodel?
A current Paragraph IV campaign against conventional Parlodel is unlikely to be commercially significant. Paragraph IV certifications are used when a generic applicant contests an Orange Book patent. Because Parlodel is an old product with established generics, the main patent challenge period has passed.
Paragraph IV activity could arise for a new bromocriptine product if the reference sponsor listed later patents covering a reformulated product. That scenario would involve the later product’s NDA and patent estate, not the original Parlodel tablets or capsules.
Does Parlodel face biosimilar risk?
No. Parlodel is a small-molecule drug, not a biologic. It is exposed to generic competition under the abbreviated new drug application pathway, not biosimilar competition under the Public Health Service Act.
The distinction matters commercially:
| Issue |
Parlodel |
| FDA pathway for competitors |
ANDA |
| Biosimilar interchangeability |
Not applicable |
| Reference biologic designation |
Not applicable |
| Bioequivalence requirement |
Applicable |
| Main competitive threat |
Generic bromocriptine and therapeutic substitutes |
What regulatory status does Parlodel have?
Parlodel is an FDA-approved prescription drug. Its regulatory value is based on an established safety and efficacy record rather than current exclusivity.
Bromocriptine products have different regulatory histories depending on the indication and formulation. Traditional Parlodel products should not be conflated with Cycloset, which received approval for type 2 diabetes as a distinct product. The two products contain bromocriptine mesylate but have different labeling, dosing and regulatory positioning [1,3].
FDA labeling continues to identify clinically important risks, including hypotension, somnolence, impulse-control symptoms and rare serious events associated with ergot-derived dopamine agonists. These risks can affect prescriber selection and post-market demand.
What formulations are protected by Parlodel?
Conventional Parlodel tablets and capsules do not have an active formulation moat comparable to newer extended-release or device-based products. The formulation is relatively simple, and generic competition is technically feasible.
Potential barriers are operational rather than patent-based:
- Sourcing bromocriptine mesylate.
- Maintaining content uniformity at low doses.
- Managing impurity profiles.
- Demonstrating bioequivalence.
- Maintaining reliable supply of small-volume dosage strengths.
- Meeting regional manufacturing and quality requirements.
These factors can produce temporary shortages or supplier concentration, but they do not create durable exclusivity.
What licensing deals affect Parlodel?
No major current licensing transaction appears to be tied specifically to the conventional Parlodel brand. The original product’s commercial history involved legacy pharmaceutical ownership and distribution arrangements, but its present economic value is primarily that of a mature genericized medicine.
Licensing activity is more likely around:
- New bromocriptine delivery systems.
- Combination endocrine products.
- Reformulated oral or injectable products.
- Regional commercialization rights.
- Specialty generics in markets with limited supplier competition.
A licensing transaction involving bromocriptine would therefore be more likely to target a new formulation or geographic market than the legacy Parlodel brand.
What litigation affects Parlodel?
There is no widely recognized current U.S. patent litigation campaign that materially threatens conventional Parlodel. Product liability, labeling and regulatory disputes remain legally possible, but they should be separated from patent litigation.
The most relevant litigation categories are:
| Litigation type |
Current relevance |
| Orange Book patent litigation |
Low for conventional Parlodel |
| ANDA Paragraph IV litigation |
Low unless tied to a later product patent |
| Product liability |
Possible, based on adverse-event allegations |
| Manufacturing disputes |
Possible at supplier or contract-manufacturing level |
| Trademark disputes |
Possible in individual jurisdictions |
| Distribution disputes |
Possible where supply is constrained |
What generic launch scenarios exist?
For conventional Parlodel, the generic launch has already occurred. Future commercial scenarios concern supply, pricing and portfolio rationalization.
Base case
Generic bromocriptine retains most prescription volume. Parlodel remains available in selected markets but has limited revenue and low promotional support.
Upside case
A supply disruption, generic withdrawal or regional shortage temporarily increases demand for the branded product. The effect would likely be episodic rather than structural.
Downside case
Manufacturers discontinue low-volume strengths, pharmacies substitute more aggressively, and prescribers shift further toward cabergoline or newer therapies. Parlodel becomes commercially marginal in additional markets.
Reformulation case
A sponsor develops a differentiated bromocriptine product with improved dosing, tolerability or delivery. The value would come from new patents and clinical positioning, not from the legacy Parlodel label.
How strong is the Parlodel patent estate?
The patent estate is weak as a current commercial asset. It has four defining characteristics:
- No meaningful active composition-of-matter protection.
- No apparent current barrier to ordinary generic entry.
- Limited value in historical method-of-use claims.
- Greater relevance of manufacturing and supply execution than patent exclusion.
The brand’s residual value is based on name recognition, regulatory history, physician familiarity and availability, not patent power.
What is the competitive outlook for Parlodel?
Parlodel operates in a crowded and mature therapeutic environment. Its competitors include generic bromocriptine, cabergoline, levodopa and other dopamine agonists for Parkinson’s disease, and modern endocrine therapies for acromegaly.
The product can retain a niche where:
- A physician has long experience with bromocriptine.
- A patient is stable and does not require switching.
- Cabergoline is unsuitable.
- A specific clinical history favors bromocriptine.
- Local availability or reimbursement supports the product.
Growth is unlikely without a new formulation, indication or commercial strategy. The conventional brand does not have a clear path to significant revenue expansion.
Key Takeaways
- Parlodel is a mature bromocriptine brand with no meaningful original patent exclusivity remaining.
- Generic bromocriptine is the primary commercial competitor.
- Conventional Parlodel has low current patent strength and limited Paragraph IV exposure.
- Biosimilar risk does not apply because bromocriptine is a small molecule.
- Public filings do not report standalone Parlodel revenue, indicating limited materiality as a separately disclosed commercial asset.
- Hyperprolactinemia is the most relevant continuing market, but cabergoline limits growth.
- Acromegaly and Parkinson’s disease contribute less commercial momentum because newer therapies have displaced bromocriptine in many treatment settings.
- Any meaningful value creation would require a differentiated formulation, new indication, supply advantage or targeted geographic strategy.
FAQs
Is Parlodel still available in the United States?
Bromocriptine remains available through generic products. Availability of the branded Parlodel product can vary by dosage form, distributor and market.
Is Parlodel the same drug as Cycloset?
Both contain bromocriptine mesylate, but they are separate FDA-approved products with different indications, labeling and dosing regimens.
Can a generic company launch bromocriptine without a clinical trial?
An ANDA applicant generally relies on the reference product’s existing approval and demonstrates pharmaceutical equivalence and bioequivalence rather than repeating full clinical efficacy trials.
Why might a patient still receive Parlodel instead of generic bromocriptine?
Possible reasons include physician preference, continuity of therapy, local availability, payer coverage, or a patient-specific response to a particular product.
Could a new bromocriptine product regain exclusivity?
Yes. A new product could potentially obtain patents or regulatory exclusivity for a differentiated formulation, delivery system, combination, indication or manufacturing process. That protection would apply to the new product, not automatically to legacy Parlodel.
References
-
U.S. Food and Drug Administration. (n.d.). Parlodel (bromocriptine mesylate) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Parlodel, NDA 017962. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Cycloset (bromocriptine mesylate) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Novartis AG. (n.d.). Annual reports and financial results. https://www.novartis.com/investors/financial-data/annual-reporting
